Is this you?
Request access for Diablo Clinical Research with your @diabloclinical.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Diablo Clinical Research
Unclaimed profileIndependent Network · Walnut Creek, California · ~1 sites
Intera lens
ICP 3Lift (cardio sample) 0.57Recruit soph 0.43
Quality Scorecard (1–100)
Overall75Recruit67Ops85Sponsor75Ther73
Performance (observed)
Historical trials
289
Completed
217
Terminated/Withdrawn
20
Completion rate
92%
Active now
50
Phase 2
89
Phase 3
129
Realized enrollment
404,375
First study year
1999
Years active
27
Match confidence
high
Enrollment velocity (inf)
14,977
Therapeutic
Areas
Endocrinology (diabetes), Cardiovascular, Metabolic conditions
Specialties
Diabetes (core), Cardiology, Metabolic/Renal, CNS, Pulmonology, Vaccines; Phase I-III
Breadth (conditions)
172
Languages
English + Spanish (detected)
States
CA
Recruitment (web observed)
Trial Finder
Yes
Patient database
Y
Recruitment pages
Yes
SEO
Good; 30-year history, 1000+ studies, now part of Flourish
Capability notes
1,000+ studies completed (as Diablo); 18,000+ patient database; Phase 1-3 trials; on-site outpatient and inpatient units; experienced MDs (25+ years) and senior staff (20+ years)
Relationships
Sponsors
Pfizer; Eli Lilly and Company; Novo Nordisk A/S; Medtronic MiniMed, Inc.; BioNTech SE; Abbott Diabetes Care
CROs
Parexel
Owner / parent
Flourish Research (Genstar Capital), acquired Feb 2025
Funding
Acquired by Flourish Research (PE-backed)
Acquisitions
Acquired by Flourish Research (February 2026)
Expansion
Y - Acquired by Flourish Research (Feb 2026); geographic expansion planned
Recent hiring
Y - Clinical Research Coordinators (2025 positions)
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
kabdullah@flourishresearch.com
Tech & DCT
Builds tech
Unknown
Home visits
Possible (on-site inpatient units)
Tech stack
Unknown
Recruiting visible
N
Notes
Limited fit: Single-site facility (Walnut Creek, CA) recently acquired by Flourish Research (PE-backed). Now part of larger network but historically standalone. Strong experience (1,000+ studies) but not recruitment-focused marketing. Narrow therapeutic focus (endocrinology/metabolic). Part of roll-up but limited evidence of independent growth. [Validated: 13 active recruiting cardiometabolic trials on ClinicalTrials.gov.]
Recommendation features (sample indication)
Ind fit 1.00Liftability 0.57Overall75
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.